Publicacions en què col·labora amb Alejandro Forner (13)

2024

  1. Evidence and choice: The BCLC vision for tailoring clinical decision-making

    Journal of Hepatology

2023

  1. Corrigendum to “EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma” [J Hepatol (79) (2023) 181–208, (S016882782300185X), (10.1016/j.jhep.2023.03.010)]

    Journal of Hepatology

  2. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma

    Journal of Hepatology

  3. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma

    Journal of Hepatology, Vol. 79, Núm. 1, pp. 181-208

2022

  1. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

    Journal of Hepatology, Vol. 76, Núm. 3, pp. 681-693

2021

  1. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

    JHEP Reports, Vol. 3, Núm. 3

  2. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH

    Medicina Clinica, Vol. 156, Núm. 9, pp. 463.e1-463.e30

2018

  1. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

    American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522

2017

  1. Human immunodeficiency virus–infected liver transplant recipients with incidental hepatocellular carcinoma: A prospective multicenter nationwide cohort study

    Liver Transplantation, Vol. 23, Núm. 5, pp. 645-651

2016

  1. Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH

    Medicina Clinica, Vol. 146, Núm. 11, pp. 511.e1-511.e22

  2. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

2011

  1. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization

    Cancer Treatment Reviews, Vol. 37, Núm. 3, pp. 212-220

2009

  1. Diagnóstico y tratamiento del carcinoma hepatocelular

    Medicina Clinica, Vol. 132, Núm. 7, pp. 272-287